Insulin detemir versus insulin glargine for type 2 diabetes mellitus

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 12, 2011, Pages

  Swinnen, Sanne G ^a   Simon, Airin C R ^a   Holleman, Frits ^a   Hoekstra, Joost B ^a   Devries, J Hans ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN DETEMIR; INSULIN GLARGINE; ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLARGINE; GLYCOSYLATED HEMOGLOBIN; INSULIN;

BODY WEIGHT DISORDER; COST; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESISTANCE; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INJECTION SITE REACTION; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; WEIGHT GAIN; WEIGHT REDUCTION; BLOOD; META ANALYSIS; METABOLISM;

DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79960977048     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006383.pub2     Document Type: Review

References (42)

1. Hollander P, Cooper J, Bregnhøi J, Pedersen CB. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clinical Therapeutics 2008;30:1976-87.
2. Raskin P, Gylvin T, Weng W, Chaykin L. Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. Diabetes Metabolism Research and Reviews 2009;25:542-8.
3. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008;51:408-16.
4. Swinnen SG, Dain MP, Aronson R, Davies M, Gerstein HC, Pfeiffer AF, et al. A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs. Diabetes Care 2010;33(6):1176-8. [MEDLINE: 20200301]
5. King AB. Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: A double-blind, randomized, crossover study. Diabetes, Obesity and Metabolism 2009;11:69-71.
6. Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes, Obesity and Metabolism 2007;9:290-9.
7. P. Lucidi, P. Rosetti, F. Porcellati, P. Candeloro, P. Cioli, S. Marzotti, et al. Basal insulin NPH, glargine and detemir in type 2 diabetes: hepatospecificity, effects on glucose and lipid metabolism, and pancreatic islet alpha and beta cell rest: a PK-PD study. Diabetologia. 2010; Vol. 53:S391.
8. Matsuura K, Mori Y, Itoh Y, Yokoyama J, Tajima N. Effect of miglitol on 24-hour glucose fluctuation in type 2 diabetic patients treated with long-acting insulin glargine or detemir as single agents as assessed by using continuous glucose monitoring. Diabetes. 2009; Vol. 58:A131.
9. Basal Insulins - Pharmacodynamics. ClinicalTrials.gov 2007.
10. Weight gain, eating patterns and development of body composition during initiation of basal insulin therapy in patients with type 2 diabetes: a comparison of insulin detemir and insulin glargine. ClinicalTrials.gov 2008.
11. Effects of adding basal insulin on endothelial progenitor cell levels in poorly-controlled type 2 diabetic patients with cardiovascular disease. A randomised cross-over study comparing insulin detemir and glargine. ClinicalTrials.gov 2008.
12. Effects of basal insulin analogue detemir on body composition, epicardial fat and energy metabolism. ClinicalTrials.gov 2009.
13. A 26-week randomised, multinational, open-labelled, 2-armed, parallel group, treat-to-target once-daily treatment trial with insulin detemir versus insulin glargine, both in combination with metformin in subjects with type 2 diabetes. ClinicalTrials.gov 2009.
14. Albright ES, Desmond R, Bell DS. Efficacy of conversion from bedtime NPH insulin injection to once- or twice-daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy. Diabetes Care 2004;27(2):632-2. [MEDLINE: 14747268]
15. Ashwell SG, Gebbie J, Home PD. Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart. Diabetic Medicine 2006;23(8):879-86. [MEDLINE: 16911626]
16. Bolli GB, Di Marchi RD, Park GD, Pramming S, Koivisto VA. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia 1999;42:1151-67.
17. Chapman TM, Perry CM. Insulin detemir: A review of its use in the management of type 1 and 2 diabetes mellitus. Drugs 2004;64:2577-95.
18. DeVries JH. To: Scholtz HE, Pretorius SG, Wessels DH, Becker RHA (2005) Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Diabetologia 2005;48(10):1988-95. [MEDLINE: 16520920]
19. Havelund S, Plum A, Ribel U, Jonassen I, Volund A, Markussen J, et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharmaceutical research 2004;21:1498-504.
20. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000;23(5):644-9. [MEDLINE: 10834424]
21. Heise T, Nosek L, Ronn BB, Endahl L, Heinemann L, Kapitza C, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004;53:1614-20.
22. Hermansen K, Davies M, Derezinski T, Martinez G, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with type 2 diabetes. Diabetes Care 2006;29:1269-74.
23. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21(11):1539-58.
24. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. BMJ 2003;327:557-60.
25. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
26. Holleman F, Gale EA. Nice insulins, pity about the evidence. Diabetologia 2007;51(4):689-91. [MEDLINE: 17634918]
27. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. The New England Journal of Medicine 2008;359(15):1577-89. [MEDLINE: 18784090]
28. Horvath K, Jeitler K, Berghold A, Plank J, Pieber TR, Siebenhofer A. Long acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: 10.1002/14651858.CD005613.pub3]
29. Lau J, Ioannidis JPA, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. BMJ 2006;333:597-600.
30. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA Statement for Reporting Systematic and Meta-Analyses of Studies That Evaluate Interventions: Explanation and Elaboration. PLoS Med 1999;6(7):1-28. [DOI: 10.1371/journal.pmed.1000100]
31. Mullins P, Sharplin P, Yki-Jarvinen H, Riddle MC, Haring HU. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus. Clinical Therapeutics 2007;29(8):1607-19. [MEDLINE: 17919543]
32. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetologia 2006;49:1711-21.
33. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2009;32(1):193-203. [MEDLINE: 18945920]
34. Plank J, Bodenlenz M, Sinner F, Magnes C, Görzer E, Regittnig W, et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 2005;28:1107-12.
35. Riddle MC, Rosenstock J, Gerich J, Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26(11):3080-6. [MEDLINE: 14578243]
36. Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 2005;28:950-5.
37. Sterne JAC, Egger M, Davey Smith G. Investigating and dealing with publication and other biases. In: Egger M, Davey Smith G, Altman DG editor(s). Systematic Reviews in Health Care; Meta-analysis in Context. London: BMJ Publishing Group, 2001:189-208.
38. Swinnen SG, Hoekstra JB, DeVries JH. Insulin therapy for type 2 diabetes. Diabetes Care 2009;32 Suppl 2:S253-9. [MEDLINE: 19875560]
39. Swinnen SG, Dain MP, Mauricio D, DeVries JH, Hoekstra JB, Holleman F. Continuation versus discontinuation of insulin secretagogues when initiating insulin in type 2 diabetes. Diabetes, obesity & metabolism 2010;12(10):923-5. [MEDLINE: 20920046]
40. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
41. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.
42. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53.